REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies (REVEAL)
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Sponsor: Nektar Therapeutics
Terminated
Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.
A PHASE1/PHASE2 clinical study on Colorectal Cancer and Head and Neck Squamous Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Nektar Therapeutics and has accumulated 28 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
28 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2022 — Apr 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 23 earlier versions
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2019 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2019 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nektar Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .